UNSPSC 51144504: Pyrovalerone hydrochloride

This classification denotes a cns stimulant with the molecular formula C16H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z95Z9C2201, chemically known as 1-pentanone, 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-, hydrochloride but more generally known as pyrovalerone hydrochloride, which bears US NIH Compound Identifier 14372. Most nations, for tariff and trade purposes, schedule pyrovalerone hydrochloride under HS 29339100 and SITC 51577. As of Q4 2014, PYROVALERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Pyrovalerone hydrochloride bears US NLM identifiers UMLS ID C0951428 and NCI Concept Code C73830. SMILES: CCCC(C(=O)C1CCC(CC1)C)N2CCCC2.CL.

UNSPSC 51144504 Pyrovalerone hydrochloride is a Commodity code that in recent state and local procurement activity encompasses naloxone, pharmaceutical products, and drug deactivation systems procured for public health and emergency response purposes. The issuing bodies soliciting under this code span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission represent recent active buyers. The scope of work reflects purchases of finished pharmaceutical products and related medical supplies—naloxone units for community health distribution, generic multi-source pharmaceuticals and over-the-counter products for state and local facilities, and drug deactivation systems for public safety applications. Vendors must typically comply with Good Manufacturing Practices, Drug Supply Chain Security Act certification, FDA requirements, and federal workplace requirements including E-Verify. Contracts frequently specify insurance coverage, shelf-life minimums, and performance penalties.

Activity centers in Florida and Texas, with multistate cooperative purchasing agreements extending to Oregon and other jurisdictions. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with bids due July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer pharmaceutical prescriptions. The Minnesota Department of Administration's Office of State Procurement, administering the multistate MMCAP alliance, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC.